ABT

Abbott Laboratories

ABT
Closed
$130.51
Closed
$0.98(0.76%)

At close

About

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. The company is headquartered in Abbott Park, Illinois and currently employs 114,000 full-time employees. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. The company serves people in more than 160 countries.
Country

US

CEO

Mr. Robert Ford

IPO date

1937

Employees

114,000

ISIN

US0028241000

Key stats

Open

$132.41

Volume

814.28M

Market cap

$223.47B

Prev. close

$130.50

Impl / hst vl

-

Open interest

$0.00

$0.00

Day’s Range

$0.00

$99.71

52W Range

$141.01

Valuation

22
Valuation score
Overvalued
P/E
17.04
P/S
5.43
P/B
4.12
Current ratio
-
Debt / Equity
-
ROE
-
Gross margin
57.13%
Income growth
-85.64%
FCF growth
-

May

15

Dividends

The last payment date was May 15, 2025

Div. per Share

$0.59

Div. Yield

0.35%

Payout Ratio

-

Div. Growth YoY

-

Analysts estimates

Consensus rating
Buy

The average rating from top 31 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$144.01
The top 26 analysts forecasts that 12-month price may increase by 10.35%, with a low of $112.45 and a high of $166.95
$112.45
Low
$144.01
Avg
$166.95
High
Current price

Earnings

Q1 ‘25 revenue
$10.36B
Q1 ‘25 net income
$1.33B
Revenue
Net income
Previous EPS
-
Estimate EPS
$1.36
Actual EPS
Estimate EPS